Table 4

Univariable and multivariable Cox proportional hazard models assessing the impact of TR severity on adverse outcomes

At baselineNo events*
(n=426)
Cardiovascular events (n=185)UnadjustedMultivariable adjustment for age, NYHA class, AF, LVEF, SPAP, RV dysfunction, Cn and PMV interventionMultivariable adjustment for age, NYHA class, AF, LVEF, SPAP, RV dysfunction, Cn, PMV intervention and TR degree
HR (95% CI)P valueHR (95% CI)P valueHR (95% CI)P value
Age, years45.3±11.852.5±12.01.045 (1.033 to 1.058)<0.0011.037 (1.022 to 1.051)<0.0011.031 (1.015 to 1.046)<0.001
NYHA III–IV140 (33)85 (46)1.959 (1.461 to 2.628)<0.0012.174 (1.529 to 3.092)<0.0012.102 (1.479 to 2.987)<0.001
AF115 (27)80 (43)1.983 (1.474 to 2.666)<0.001
LVEF (%)62.8±7.360.8±8.50.971 (0.955 to 0.988)0.0010.969 (0.949 to 0.989)0.0020.973 (0.953 to 0.993)0.010
SPAP (mm Hg)42.2±16.845.7±18.01.010 (1.002 to 1.018)0.0101.010 (0.998 to 1.021)0.095
RV dysfunction102 (24)70 (38)1.837 (1.357 to 2.485)<0.001
Cn (mL/mm Hg)5.3±1.94.8±1.70.869 (0.789 to 0.957)0.0040.880 (0.780 to 0.993)0.0380.850 (0.766 to 0.944)0.002
PMV270 (63)93 (50)0.576 (0.431 to 0.769)<0.0010.438 (0.302 to 0.634)<0.0010.441 (0.305 to 0.637)<0.001
TR degrees
No or mild TR391 (92)141 (76)ReferenceReferenceReference
Moderate TR27 (6)24 (13)2.132 (1.382 to 3.290)0.0011.908 (1.149 to 3.168)0.013
Severe TR8 (2)20 (11)3.650 (2.283 to 5.834)<0.0012.298 (1.279 to 4.132)0.005
  • *Five patients (0.8%) died from non-cardiac causes, and in 29 patients (4.5%), follow-up data were not obtained.

  • †PMV performed short-term after enrolment (median of 2.3 months).

  • AF, atrial fibrillation; Cn, net atrioventricular compliance; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association; PMV, percutaneous mitral valvuloplasty; RA, right atrium; RV, right ventricular; SPAP, systolic pulmonary artery pressure; TR, tricuspid regurgitation.